Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08VBV
|
|||
| Former ID |
DIB012181
|
|||
| Drug Name |
TAP311
|
|||
| Indication | Dyslipidemia [ICD-11: 5C80-5C81; ICD-9: 272] | Phase 1 | [1] | |
| Company |
Novartis pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C34H40F6N6O4
|
|||
| Canonical SMILES |
CCC1CC(CC(N1C(=O)OC2CCC(CC2)C(=O)O)CC)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)C5=CN(N=C5)C
|
|||
| InChI |
1S/C34H40F6N6O4/c1-4-26-13-28(14-27(5-2)46(26)32(49)50-29-8-6-21(7-9-29)30(47)48)45(31-41-15-22(16-42-31)23-17-43-44(3)19-23)18-20-10-24(33(35,36)37)12-25(11-20)34(38,39)40/h10-12,15-17,19,21,26-29H,4-9,13-14,18H2,1-3H3,(H,47,48)/t21?,26-,27+,28?,29?
|
|||
| InChIKey |
KSPXRTYMEVDHAB-LTZKBQIGSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01487460) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.